Preparation, characterization, and antiproliferative activities of the Se-containing polysaccharide SeGLP-2B-1 from Se-enriched Ganoderma lucidum.
Inorganic selenite can be transformed into organic forms and bind to proteins and polysaccharides in Se-enriched submerged Ganoderma lucidum cultures. In the present study, a novel Se-containing polysaccharide, SeGLP-2B-1, was purified from the Se-enriched mycelia of G. lucidum and the antiproliferative activities against six human cancer cell lines were investigated. The Se content of SeGLP-2B-1 was 186.7 microg/g, which was 150-fold larger than that of the regular polysaccharide GLP-2B-1 (1.3 microg/g). SeGLP-2B-1 (1.06 x 10(6) Da) was composed of glucose, rhamnose, xylose, and galactose with a molar ratio of 1.000:0.652:0.443:0.227. SeGLP-2B-1 exhibited an approximately 10-fold stronger antiproliferative activity against six human cancer cell lines as compared to GLP-2B-1. Thus, Se is believed to play an important role in increasing the antiproliferative property of SeGLP-2B-1. These findings indicate that SeGLP-2B-1 may serve as a dietary Se supplement.
Shang
Dejing
D
Liaoning Provincial Key Laboratory of Biotechnology and Drug Discovery, Faculty of Life Science, Liaoning Normal University, Dalian 116029, China. djshang@lnnu.edu.cn
Zhang
Jianing
J
Wen
Lei
L
Li
Yang
Y
Cui
Qiao
Q
D000970:Antineoplastic Agents / Q000494:pharmacology; D001943:Breast Neoplasms; D006528:Carcinoma, Hepatocellular; D002453:Cell Cycle / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects*; D045744:Cell Line, Tumor; D055598:Chemical Phenomena; D019587:Dietary Supplements; D005260:Female; D032902:Ganoderma / Q000737:chemistry*; D006367:HeLa Cells; D006801:Humans; D020014:K562 Cells; D008113:Liver Neoplasms; D025282:Mycelium / Q000737:chemistry*; D009942:Organometallic Compounds / Q000737:chemistry / Q000302:isolation & purification* / Q000494:pharmacology*; D011134:Polysaccharides / Q000032:analysis / Q000737:chemistry / Q000302:isolation & purification* / Q000494:pharmacology*; D012643:Selenium / Q000008:administration & dosage* / Q000032:analysis
D000970:Antineoplastic Agents; D009942:Organometallic Compounds; D011134:Polysaccharides; C545092:SeGLP-2B-1; D012643:Selenium